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Summary
Background: Hsp90 is an environmentally contingent molec-
ular chaperone that influences the form and function of diverse
regulators of cellular signaling. Hsp90 potentiates the evolu-
tion of fungal drug resistance by enabling crucial cellular
stress responses. Here we demonstrate that in the leading
fungal pathogen of humans, Candida albicans, Hsp90 governs
cellular circuitry required not only for drug resistance but also
for the key morphogenetic transition from yeast to filamentous
growth that is crucial for virulence. This transition is normally
regulated by environmental cues, such as exposure to serum,
that are contingent upon elevated temperature to induce
morphogenesis. The basis for this temperature dependence
has remained enigmatic.
Results:We show that compromising Hsp90 function pharma-
cologically or genetically induces a transition from yeast to fila-
mentous growth in the absence of external cues. Elevated
temperature relieves Hsp90-mediated repression of the
morphogenetic program. Hsp90 regulates morphogenetic
circuitry by repressing Ras1-PKA signaling. Modest Hsp90
compromise enhances the phenotypic effects of activated
Ras1 signaling whereas deletion of positive regulators of the
Ras1-PKA cascade blocks the morphogenetic response to
Hsp90 inhibition. Consistent with the requirement for morpho-
genetic flexibility for virulence, depletion of C. albicans Hsp90
attenuates virulence in a murine model of systemic disease.
Conclusions: Hsp90 governs the integration of environmental
cues with cellular signaling to orchestrate fungal morphogen-
esis and virulence, suggesting new therapeutic strategies for
life-threatening infectious disease. Hsp90’s capacity to govern
a key developmental program in response to temperature
change provides a new mechanism that complements the
elegant repertoire that organisms utilize to sense temperature.
Introduction
Hsp90 is an essential molecular chaperone that regulates the
form and function of diverse client proteins in all eukaryotes
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and dwell in incompletely folded or aggregation-prone states.
They dynamically cycle through complexes with Hsp90 and
cochaperones until the proper signal engenders their activa-
tion. As a consequence of its function in chaperoning regula-
tors of cell circuitry, Hsp90 has a capacity to modulate the
translation of genotype to phenotype [4]. Hsp90 can buffer
the expression of genetic and epigenetic variation, allowing it
to be revealed in response to environmental stress [4–6].
Although Hsp90 is induced under conditions of stress, such
as increased temperature, global problems in protein folding
that ensue can overwhelm its functional capacity. As a capac-
itor for the storage and release of genetic variation, Hsp90 can
influence the emergence of new traits.
In fungi, Hsp90 potentiates the rapid evolution of drug resis-
tance [7]. Fungal pathogens are a leading cause of human
mortality worldwide, especially among immunocompromised
individuals. Fungal infections are notoriously difficult to treat
with the limited number of antifungal drugs available that
have selective toxicity to fungi, which share close evolutionary
relationships with their human hosts [4]. Therapeutic chal-
lenges are exacerbated as resistance has emerged for all clin-
ically useful antifungals. Hsp90 enables the emergence of
resistance to the most widely deployed antifungals, the azoles,
which exert cell membrane stress [7]. Genetic or pharmaco-
logical inhibition of Hsp90 function blocks the emergence of
azole resistance in the model yeast Saccharomyces cerevisiae
and the pathogenic yeast Candida albicans [7]. Compromising
Hsp90 function enhances the therapeutic efficacy of azoles in
two metazoan models of disseminated C. albicans disease [8].
C. albicans reigns as the leading fungal pathogen of hu-
mans, and its virulence is intimately coupled with morphoge-
netic plasticity. Growth forms range from unicellular budding
yeast to true hyphae composed of filaments with parallel-
sided walls lacking constrictions between cells [9, 10]. Pheno-
typically intermediate pseudohyphal forms are composed of
filaments of elongated cells demarked by constrictions.
Because of phenotypic and regulatory similarities [11, 12],
hyphal and pseudohyphal forms are often referred to collec-
tively as filamentous forms. Morphogenetic plasticity is impli-
cated in virulence as indicated by the fact that mutants defec-
tive in the yeast to filament transition are attenuated in
virulence [9, 13]. Filaments have invasive properties that can
promote tissue penetration and escape from immune cells,
whereas yeast are suited for dissemination in the bloodstream.
The coupling between morphogenesis and virulence is rein-
forced as genes that govern morphogenesis are coregulated
with those encoding virulence factors such as proteases and
adhesins [14].
C. albicans morphogenesis is induced by distinct environ-
mental cues and is governed by complex regulatory networks.
Morphogenesis is induced by signals such as nutrient limita-
tion, pH, CO2, and serum [15]. Ras1, a small GTPase, regulates
two key signal transduction pathways that control morpho-
genesis, the mitogen-activated protein (MAP) kinase path-
way and the cAMP-protein kinase A (PKA) pathway [16].
The cAMP-PKA pathway has the most prominent role in
C. albicans morphogenesis such that its inactivation blocks
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622filamentation in diverse conditions, including exposure to
serum. The active component of serum that induces filamenta-
tion is bacterial cell wall fragments that directly stimulate the
production of cAMP [17]. Notably, the induction of filamentous
growth by the vast majority of environmental cues, including
serum, requires a concomitant increase in temperature, and
the basis for this requirement has remained enigmatic.
We report here that Hsp90 orchestratesC. albicansmorpho-
genesis and that it is relief of Hsp90-mediated repression of
the morphogenetic program that underpins the requirement
for elevated temperature to induce filamentous growth.
Compromising Hsp90 function induces a yeast to filament
transition via the Ras1-PKA cascade and attenuates virulence
in a murine model of systemic disease. Our results establish
an entirely new role for Hsp90 in this central developmental
process.
Results
Hsp90 Regulates theC. albicansMorphogenetic Transition
from Yeast to Filamentous Growth
We initially compromised Hsp90 function pharmacologically
with structurally unrelated inhibitors geldanamycin (GdA) or
radicicol (RAD) that bind with high affinity to Hsp90’s unusual
ATP binding pocket [4]. In liquid rich medium at 30C, C. albi-
cans normally grows as a budding yeast. Inhibition of Hsp90
induced a profound morphogenetic switch to filamentous
growth (Figure 1A; Figure S1A available online). Next, we
Figure 1. Hsp90 Regulates the C. albicans
Morphogenetic Transition from Yeast to Filamen-
tous Growth
(A) Pharmacological inhibition of Hsp90 with gel-
danamycin (GdA) induced filamentation. Wild-
type cells (SN95) were incubated in rich medium
(YPD) at 30C for 24 hr with GdA, as indicated.
(B) Genetic depletion of Hsp90 induced filamen-
tous growth. Hsp90 levels were reduced by
20 mg/mL DOX for tetO-HSP90/hsp90D and by
glucose for MAL2p-HSP90/hsp90D at 30C for
24 hr.
Scale bar represents 10 mm.
(C) Depletion of Hsp90 induced filamentous and
invasive growth on solid medium. 1, HSP90/
HSP90; 2, HSP90/hsp90D; 3, MAL2p-HSP90/
hsp90D. Strains were grown on rich medium
with maltose (YPM) or glucose (YPD) for 2 days
and washed with water to remove noninvasive
cells.
engineered strains in which the only
HSP90 allele was regulated by one of
two repressible promoters. In our
system, transcription from tetO is
repressed by tetracycline or the analog
doxycyline and induced in their
absence; transcription from MAL2p is
repressed by glucose and induced by
maltose (Figure S1B). Transcriptional
repression of HSP90 from either
promoter induced a yeast-to-filament
transition (Figure 1B). This transition
was also observed on solid medium,
coupled with robust invasion into the
agar (Figure 1C). Neither the addition of
doxycycline nor the change in carbon source affected growth
or morphogenesis of strains in which HSP90 was not subject
to transcriptional repression (Figure 1C; Figures S1C–S1E).
The magnitude of Hsp90 depletion required to induce filamen-
tation reduced growth rates (Figure S1C) but had little effect on
stationary phase cell density (Figure S1D). Further, cells were
able to revert to yeast upon relief of Hsp90 inhibition (Fig-
ure S2). Thus, Hsp90 reversibly governs the morphogenetic
transition from yeast to filamentous growth.
Induction of Filamentous Growth by Standard
Environmental Signals Requires Relief of Hsp90-Mediated
Repression of the Morphogenetic Program
A striking requirement for most conditions that induce filamen-
tation, including serum, is an elevated temperature of 37C, yet
the basis for this requirement has remained enigmatic [16].
Given that Hsp90 function can be compromised at elevated
temperatures because of global problems in protein folding
and given its role in morphogenesis (Figure 1), we took four
complementary approaches to determine if the temperature
requirement is to relieve Hsp90-mediated repression of the
morphogenetic program.
First, we tested whether a modest reduction of Hsp90 could
bypass the temperature requirement for serum-induced fila-
mentation. Exposure to serum at 30C did not induce filamen-
tation in a strain with wild-type or heterozygous HSP90 levels
nor did the moderate reduction of Hsp90 achieved when the
native HSP90 promoter was replaced with MAL2p and the
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serum (Figure 2A; Figure S1B). However, the reduction of
Hsp90 in the MAL2p-HSP90/hsp90D strain did enable serum
to induce morphogenesis at 30C (Figure 2A), consistent
with the temperature requirement being rooted in relief of
Hsp90-mediated repression.
Second, we postulated that if elevated temperature were
required to relieve Hsp90-mediated repression of filamenta-
tion, then a lower dose of Hsp90 inhibitor would suffice to
induce filamentous growth at 37C compared to 30C. We
found that a high dose of Hsp90 inhibitor induced morphogen-
esis at either temperature, while a lower dose induced
morphogenesis only at 37C (Figure 2B). That less Hsp90
inhibitor is required to induce filamentation at elevated
temperature suggests that Hsp90’s functional capacity may
be overwhelmed.
Third, to test whether Hsp90’s functional capacity is over-
whelmed in conditions favoring filamentation, we exploited
activation of the heat shock response. In S. cerevisiae, Hsf1
governs transcriptional responses to stress by remodeling
Figure 2. Induction of Filamentous Growth in
Response to Serum Requires Relief from
Hsp90-Mediated Repression of the Morphoge-
netic Program
(A) Modest reduction of Hsp90 bypassed the
temperature requirement for serum-induced fila-
mentation. Strains were incubated in YPD at 30C
for 6 hr with serum, as indicated.
(B) A lower dose of Hsp90 inhibitor was sufficient
to induce filamentation at 37C compared to
30C. Morphology of the wild-type was moni-
tored after 6 hr in YPD.
Scale bar represents 10 mm.
(C) Filament-inducing conditions stimulated an
Hsp90-mediated heat shock response. Induction
of the heat shock response was monitored with
HSP70p-lacZ. b-galactosidase activity was
measured after incubation in YPD with or without
serum for 1 hr. Data are means6 SD for triplicate
samples.
(D) Filament-inducing conditions compromised
activity of the Hsp90 client protein calcineurin.
Calcineurin activity was monitored with UTR2p-
lacZ. Calcineurin was activated with 200 mM
CaCl2 and b-galactosidase activity was
measured after incubation in YPD with or without
10% serum for 3 hr. Data are means 6 SD for
triplicate samples.
expression ofw3% of the genome [18].
Hsp90 exerts a repressive effect on
Hsf1 such that compromising Hsp90
leads to induction of the heat shock
response, upregulating heat shock
proteins among other targets [19]. We
monitored expression of a heat shock
reporter by using a construct with the
HSP70 promoter containing three heat
shock elements fused to lacZ, integrated
at the native HSP70 locus. As expected,
inhibition of Hsp90 with GdA induced
expression from the HSP70 promoter
(Figure S3A). Either an increase in
temperature from 30C to 37C or expo-
sure to serum at 30C yielded an
intermediate induction (p < 0.001, ANOVA, Figure 2C). The
combination of serum and elevated temperature resulted in
further induction of the heat shock response (p < 0.01), consis-
tent with Hsp90’s functional capacity being compromised by
conditions that induce filamentous growth.
Fourth, to validate that Hsp90’s functional capacity is over-
whelmed by conditions favoring filamentation, we monitored
activation of the Hsp90 client protein calcineurin, which regu-
lates stress responses [4, 20]. Hsp90 physically interacts with
calcineurin and keeps it poised for activation in response to
calcium. Upon activation, calcineurin dephosphorylates target
proteins including the transcription factor Crz1 [21, 22]. De-
phosphorylated Crz1 translocates to the nucleus and binds
calcineurin-dependent response elements (CDREs) to induce
transcription. We used a construct with the UTR2 promoter,
which contains a CDRE and is regulated by calcineurin [21],
fused to lacZ. Inhibition of Hsp90 with GdA reduced calci-
neurin activation in response to CaCl2 (Figure S3B). Fila-
ment-inducing conditions of serum at 37C reduced calci-
neurin activation in response to CaCl2 relative to serum at
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Hsp90 function.
Hsp90 Regulates Morphogenesis via the Ras1-PKA
Cascade
We screened a panel of previously characterized mutants to
identify those blocked in filamentation in response to Hsp90
inhibition. Positive regulators of the Ras1-PKA pathway were
blocked in the morphogenetic response (Figures 3A and 3B;
Figure S4). Ras1 cycles between an inactive GDP-bound and
an active GTP-bound state and regulates filamentation in
response to serum and other stimuli [16, 23, 24]. Ras1 is acti-
vated by the guanine exchange factor Cdc25 and stimulates
the adenylyl cyclase activity of Cdc35, which works with
cyclase-associated protein Cap1 to produce cAMP [25, 26].
Elevated intracellular cAMP levels activate the catalytic
subunits of PKA (Tpk1 and Tpk2). We found that ras1, cdc25,
and cdc35 null mutants were completely blocked in the
morphogenetic response whereas cap1 mutants showed
Figure 3. Hsp90 Regulates Morphogenesis via
Ras1-PKA Signaling
(A) Mutants of positive regulators of the Ras1-
PKA pathway were blocked in morphogenetic
response to Hsp90 inhibition. Mutants were
incubated in YPD at 30C for 6 hr with GdA, as
indicated. Depletion of PKA without compro-
mising growth was achieved by culturing the
PCK1p-TPK1/tpk1D tpk2D/tpk2D mutant in 1:1
YPM:YPD. Scale bar represents 10 mm.
(B) Schematic of the Ras1-PKA cascade.
(C) Quantification of HWP1 transcript levels,
measured by quantitative RT-PCR after growth
at 30C for 6 hr with GdA, as indicated. HWP1
transcript levels were normalized to GPD1.
Levels are expressed relative to the untreated
wild-type sample, which was set to 1. Data are
means 6 SD for triplicate samples.
(D) Positive epistasis between Ras1 and Hsp90.
Strains were grown on YPD at 30C for 3 days.
Scale bar represents 250 mm.
a partial block in the presence of Hsp90
inhibitors. Neither tpk1 nor tpk2 null
mutants were blocked, consistent with
their partial redundancy [27]; however,
transcriptional repression of the only
TPK1 allele in a strain lacking TPK2
completely blocked filamentation. These
mutants showed comparable blocks in
serum-induced filamentation, consistent
with both Hsp90 and serum acting
through this pathway (Figure S5). PKA
activates Efg1, which activates a tran-
scriptional program governing morpho-
genesis in response to many cues [27,
28]. Whereas efg1 null mutants were
blocked in response to serum (Fig-
ure S5), they filament in response to
Hsp90 inhibition (Figure 3A), suggesting
that Hsp90 signals through other down-
stream targets of PKA.
To assess the morphogenetic
response to Hsp90 inhibition by an inde-
pendent and quantitative method, we
analyzed transcript levels of the well-characterized hyphal
wall protein 1, HWP1. HWP1 is expressed exclusively in fila-
mentous forms and is regulated by Ras1-PKA signaling via
Efg1 in concert with other regulators [29]. In the wild-type,
inhibition of Hsp90 caused more than 250-fold induction of
HWP1, measured by quantitative real-time RT-PCR relative
to the constitutiveGPD1 control (Figure 3C). In contrast, induc-
tion of HWP1 was blocked in the ras1, cdc25, or cdc35
mutants, consistent with the morphological block as yeast.
There was a moderate 18-fold induction of HWP1 in the
cap1 mutant upon Hsp90 inhibition, reflecting its partial defect
in filamentation. High-level HWP1 induction was evident in
the tpk1 and tpk2 mutants whereas depletion of PKA blocked
induction. There was no significant induction of HWP1 in the
efg1 mutant, consistent with Efg1’s established role in HWP1
regulation [29].
Next, we tested for genetic interactions in mutants with acti-
vated Ras1 signaling or reduced Hsp90. A strain harboring
one dominant active RAS1 allele (Ras1V13) demonstrated
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but remained as yeast with smooth colonies on solid rich
medium at 30C (Figure 3D). A strain heterozygous for
HSP90 remained as yeast with smooth colonies under these
conditions. However, the combination of Ras1V13 and reduced
Hsp90 levels yielded enhanced filamentation in both solid and
liquid medium (Figure 3D; Figure S6A). Deletion of IRA2, which
encodes the GTPase-activating protein that cycles Ras1 to the
inactive state, also stimulates Ras1 signaling [31]. Deletion of
one IRA2 allele had no effect in liquid in a strain with wild-
type Hsp90; however, deleting one HSP90 allele in the IRA2D
heterozygote enhanced filamentation (Figure S6B). Thus,
genetic epistasis suggests that Hsp90 regulates morphogen-
esis by repressing Ras1-PKA signaling until the appropriate
cues compromise Hsp90, relieving repression of the morpho-
genetic program.
Hsp90 Does Not Repress Ras1-PKA Signaling
by Stabilizing Negative Regulators of the Pathway Ira2,
Pde1, or Pde2
There are two models by which Hsp90 could repress Ras1-
PKA signaling. Hsp90 could physically interact with a positive
regulator and maintain an inactive conformation until Hsp90 is
compromised. Alternatively, Hsp90 could interact with a nega-
tive regulator and keep it poised for activation. Therefore,
compromising Hsp90 function should either phenocopy
a gain-of-function allele of a positive signaling component of
the Ras1-PKA pathway or a loss-of-function allele of a negative
regulator. More complicated models involving Hsp90 regula-
tion of multiple pathway components are also conceivable.
Figure 4. Hsp90 Does Not Repress Ras1-PKA
Signaling via Negative Regulators of the Pathway
Loss of function of negative regulators of the
Ras1-PKA cascade did not phenocopy Hsp90
inhibition whereas inhibition of Hsp90 induced fil-
amentation. Cells were incubated in YPD at 30C
for 6 hr with GdA, as indicated. Scale bar repre-
sents 10 mm.
Figure 5. Quorum-Sensing Molecules Block Fila-
mentous Growth Induced by Serum but Not by
Hsp90 Inhibition
Left panels, a wild-type strain was cultured in
YPD at 37C for 6 hr with serum, dodecanol, or
farnesol, as indicated. Right panels, the strain
was cultured in YPD at 30C for 6 hr with GdA,
dodecanol, or farnesol, as indicated. Scale bar
represents 10 mm.
We tested genetically whether some
of the Ras1-PKA-negative regulators
are the sole targets of Hsp90. As
mentioned above, Ira2 is a negative
regulator of Ras1 signaling. Pde1 and Pde2 are phosphodies-
terases that degrade cAMP [32]. Null mutants of these nega-
tive regulators remained as yeast in rich medium at 30C
whereas Hsp90 inhibition induced filamentation (Figure 4).
Null mutants of the negative regulatory subunit of PKA,
Bcy1, are not viable on their own and thus could not be tested.
Thus, loss of function of Ira2, Pde1, or Pde2 does not pheno-
copy Hsp90 inhibition and Hsp90 inhibition can still induce fil-
amentation in their absence, suggesting that Hsp90 does not
regulate morphogenesis through any one of these proteins.
Quorum-Sensing Molecules Block Serum-Induced
Filamentation but Not GdA-Induced Filamentation
To determine where Hsp90 acts in the Ras1-PKA cascade, we
exploited the quorum-sensing molecules farnesol and dodec-
anol [33]. Farnesol is produced by C. albicans and represses
filamentation in dense populations. Dodecanol is an alcohol
with similar activities to 3-oxo-C12-homoserine lactone,
a signaling molecule produced by Pseudomonas aeruginosa.
Both farnesol and dodecanol inhibit filamentation induced by
serum or Ras1V13 (Figure 5 and [33]). Serum directly stimulates
Cdc35 [17] and farnesol and dodecanol block serum-induced
filamentation [33], so farnesol and dodecanol act at or below
Cdc35. In contrast, neither farnesol nor dodecanol inhibited fil-
amentation induced by Hsp90 inhibition (Figure 5). The trivial
explanation that farnesol or dodecanol are ineffective because
cells are locked as filaments is excluded given that cells can
revert to yeast upon relief of Hsp90 inhibition (Figure S2).
Thus, Hsp90 is likely to function at a point in the pathway below
Cdc35 to regulate morphogenesis.
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in a Murine Model
Hsp90’s role in morphogenesis and its essentiality suggest it
as an ideal therapeutic target. To test the impact of genetic
depletion of Hsp90 on C. albicans virulence, we employed
a murine model of systemic disease in which inoculum is deliv-
ered by tail vein injection and progresses from the blood-
stream to deep-seated infection of major organs such as the
kidney [8]. To regulate Hsp90, we exploited the tetracycline-
repressible promoter (tetO, Figure S1B). There was no signifi-
cant difference in kidney fungal burden between mice infected
with the wild-type strain or the HSP90 heterozygote (Figure 6).
In the absence of tetracycline, the strain with its only HSP90
allele regulated by tetO has comparable Hsp90 levels to
a strain in which the only HSP90 allele is under the control of
the native stress-inducible promoter (Figure S1B). Although
HSP90 expression from the native promoter is induced by
increased temperature, expression of HSP90 from tetO is not
[8]. Even in the absence of tetracycline, mice infected with
the strain with its only HSP90 allele regulated by tetO had
significantly lower kidney fungal burden than those infected
with the strain with its HSP90 allele regulated by the native
promoter (Figure 6, p < 0.001, ANOVA). Treating mice infected
with the wild-type strain or the HSP90 heterozygote with tetra-
cycline had no significant impact on fungal burden, whereas
tetracycline-induced depletion of HSP90 resulted in steriliza-
tion of the kidneys (Figure 6). Thus, Hsp90 provides an attrac-
tive therapeutic target for the treatment of life-threatening
C. albicans infection.
Discussion
Our results establish a novel role for Hsp90 in regulating devel-
opmental process. In the leading fungal pathogen of humans,
C. albicans, Hsp90 regulates the morphogenetic transition from
yeast to filamentous growth that is intimately coupled with viru-
lence (Figure 1). Hsp90 orchestrates morphogenesis by repres-
sing specific cellular signaling. Conditions that compromise
Hsp90 induce morphogenesis via the Ras1-PKA cascade.
Figure 6. Genetic Reduction of C. albicans Hsp90 Attenuates Virulence in
a Murine Model
Replacing the native HSP90 promoter with the tetO repressible promoter
yielded a significant reduction in fungal burden (p < 0.001, ANOVA), despite
the higher inoculum used. Tetracycline-mediated depletion of Hsp90 re-
sulted in sterilization of the kidney. Asterisk indicates p < 0.001. Data are
means 6 SEM.Canonical environmental cues that stimulate morphogenesis,
such as serum, require elevated temperature to alleviate
Hsp90-mediated repression of the morphogenetic program.
Thus, Hsp90 links environmental stress with cellular signaling
to regulate C. albicans morphogenesis and pathogenesis.
In the human host, where C. albicans resides as a
commensal member of the mucosal microbiota, it is poised
to respond to environmental cues that induce morphogenesis.
Decades of laboratory studies have focused on delineating the
stimuli that induce this developmental transition and the regu-
latory circuitry involved, yet the basis for the elevated temper-
ature requirement to induce filamentation in vitro has remained
obscure [9, 10, 16]. Elevated temperature is not required for fil-
amentation in specific conditions such as embedded growth
where the Czf1 pathway prevails, but is required for response
to serum, nutrient limitation, pH, and CO2 that depend on
cellular circuitry regulated by Ras1 or the Rim101-dependent
pH pathway. Marshalling four complementary approaches,
we demonstrate that compromising Hsp90 can overcome
the requirement for elevated temperature for serum-induced
filamentation and that Hsp90 function is compromised under
conditions that induce morphogenesis (Figure 2). Although
Hsp90 is induced in response to heat stress, its functional
capacity to regulate client protein activation can be over-
whelmed by global problems in protein folding. Together,
this implicates Hsp90 as a key regulator of cellular circuitry
governing morphogenesis.
Hsp90 regulates the morphogenetic program by repressing
Ras1-PKA signaling, as evidenced by both positive and nega-
tive epistasis. Our results are consistent with Hsp90 mediating
a repressive effect on a positive regulator (Figure 4). There is
precedent for such regulation, because Hsp90 represses
Hsf1 thereby regulating induction of the heat shock response
[18, 19]. Given that the quorum-sensing molecules farnesol
and dodecanol block the morphogenetic response to serum
[33], which stimulates Cdc35 [17], but do not block the
response to Hsp90 inhibition (Figure 5), Hsp90 is likely to func-
tion downstream of Cdc35. Depletion of PKA or deletion of
upstream regulators blocks the morphogenetic response to
Hsp90 inhibition, suggesting that PKA activation is dependent
upon upstream input. This contingency is consistent with
impairment of ras1 mutants in response to serum-induced fil-
amentation, despite serum stimulating the downstream factor
Cdc35 [17]. Thus, our results are consistent with a model in
which Hsp90 inhibition leads to activation of PKA and induc-
tion of filamentous growth.
Both serum and Hsp90 inhibition stimulate filamentation by
activating Ras1-PKA signaling; however, marked regulatory
differences underpin the responses. Although efg1 mutants
are blocked in the morphogenetic response to serum, they
are not blocked in response to Hsp90 inhibition (Figure 3;
Figure S5), suggesting that Hsp90 works via effectors down-
stream of PKA distinct from Efg1. That Efg1 is required to regu-
late filament-specific genes, such as HWP1 (Figure 3C), but is
not required for filamentation is reminiscent of the transcrip-
tion factor Bcr1, which is also required for filament-specific
transcription but not for filamentation [34]. Notably, genes
implicated in morphogenesis that are dependent on Efg1
in vitro are not dependent on Efg1 in a mouse, suggesting
that this regulatory circuitry is more complex than previously
appreciated [35]. Other transcriptional regulators that function
downstream of PKA signaling and are implicated inC. albicans
morphogenesis include Tec1 and Flo8 [16]. In addition to regu-
latory differences, there are also morphological differences
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Hsp90 inhibition. This likely reflects the pleiotropic impact of
Hsp90 on multiple signaling pathways in contrast to the spec-
ificity of serum stimulation of Cdc35.
Hsp90’s pleiotropic effects on growth and morphogenesis
have broad therapeutic implications. Compromising C. albi-
cans Hsp90 expression results in a significant reduction in
virulence in a murine model of systemic disease (Figure 6).
Further depletion of Hsp90 results in clearance of the infection.
Given that morphogenetic flexibility is required for virulence
and compromising Hsp90 drives filamentation, this virulence
attenuation could reflect Hsp90’s effect on morphogenesis,
virulence regulators, or basal growth. Regardless of mecha-
nism, targeting Hsp90 in the pathogen provides an attractive
therapeutic strategy. Drugs structurally related to GdA are in
advanced phase clinical trials for treating cancer [36]. At
concentrations well tolerated in humans, Hsp90 inhibitors
abrogate fungal drug resistance [7] and enhance therapeutic
efficacy of antifungals in a metazoan model of fungal disease
[8], providing another avenue by which Hsp90 could be har-
nessed to treat fungal infections.
Strikingly, compromising Hsp90 function induces a develop-
mental program in C. albicans, in contrast to other systems in
which compromising Hsp90 blocks developmental transitions.
In the slime mold Dictyostelium discoideum, Hsp90 inhibition
arrests development at the ‘‘mound’’ stage [37]. In the proto-
zoan parasitePlasmodium falciparum, Hsp90 inhibition blocks
development from ring stage to trophozoite, and in Leishmania
donovani, it blocks development in the promastigote stage
[38]. Given that Hsp90 may interact with up to 10% of the yeast
proteome [39], there will likely be myriad ways in which Hsp90
orchestrates cellular signaling governing environmentally
responsive developmental programs.
Hsp90’s capacity to sense temperature change and govern
a key developmental program provides a new mechanism that
complements the elegant repertoire that organisms utilize to
sense temperature. Intriguingly, the systemic dimorphic fungi
exhibit temperature-dependent morphogenesis in the inverse
direction from C. albicans such that they are filamentous in the
soil at ambient temperature and switch to the pathogenic
yeast form at human body temperature upon infection [40].
Hsp90’s role in C. albicans temperature-dependent morpho-
genesis raises the tantalizing possibility that it may impinge
on global morphogenetic regulators in dimorphic fungi, such
as the hybrid histidine kinase Drk1 [41]. Another distinct mech-
anism discovered in fungi is temperature-dependent splicing
that regulates the circadian clock [42]. In bacteria, thermosen-
sitive nutrient and quorum sensing governs thermotaxis via
methylation of Tsr receptors [43] and an RNA thermosensor
controls synthesis of a transcriptional regulator [44]. In
mammals, thermosensitive transient receptor potential chan-
nels in sensory neurons and skin cells relay temperature infor-
mation to the brain [45]. The multitude of distinct mechanisms
that organisms utilize to sense temperature illustrates the
stunning complexity of ways in which environmentally contin-
gent responses are transduced in biological systems.
Experimental Procedures
Strains and Culture Conditions
Strains used in this study are listed in Table S1 and their construction is
described in the Supplemental Data. C. albicans strains were cultured on
YPD (2% bacto-peptone, 1% yeast extract, and 2% glucose) or YPM (as
YPD, but with 2% maltose). Overnight cultures were grown in 5 ml of YPD
or YPM at 30C unless otherwise indicated. Cells were diluted to OD600 of0.2 and grown for the indicated time period for the following treatments:
10% fetal bovine serum (GIBCO), 10 mM geldanamycin (GdA, A.G. Scientific,
Inc.), 20 mM radicicol (A.G. Scientific, Inc.), 20 mg/mL doxycycline (BD
Biosciences), 200 mM dodecanol (Sigma Aldrich Co.), and 200 mM farnesol
(Sigma Aldrich Co.).
Plasmids
Plasmids used in this study are listed in Table S2 and their construction is
described in the Supplemental Data. Plasmids were sequenced to verify
the absence of any nonsense mutations. Primers used in this study are
listed in Table S3.
Microscopy
Imaging of cells cultured in liquid was performed by differential interference
contrast microscopy with a Zeiss Axio Imager.MI and Axiovision software
(Carl Zeiss, Inc.). Microscopy of colonies on solid media was performed
with a Zeiss Stereo Discovery.V8.
Invasive Growth
Cells were grown on YPD or YPM plates for 2 days, washed with water, and
photographed.
b-Galactosidase Assays
Cells were grown overnight in YPD at 30C, diluted to OD600 of 0.2 with treat-
ment as indicated, and grown for 1–3 hr at 30C or 37C. Protein was ex-
tracted [46, 47], and protein concentrations were determined by Bradford
analysis (Bio-Rad Laboratories, Inc.). b-galactosidase activity was
measured with the substrate ONPG (O-nitrophenyl-b-D-galactopyranoside,
Sigma Aldrich Co.), as described [46]. b-galactosidase activity is given in
units of nanomoles ONPG converted per minute per milligram of protein.
qRT-PCR
Cells were grown overnight in YPD or 1:1 YPD:YPM at 30C, diluted to OD600
of 0.2 with 10 mM GdA as indicated, and grown overnight. Cells were again
diluted to OD600 of 0.2 in the same conditions and grown to mid-log phase.
RNA was isolated and PCR was performed as described [8]. Reactions were
performed in triplicate, with oLC752 and oLC753 (GPD1) and oLC750 and
oLC751 (HWP1). Data were analyzed with iQ5 Optical System Software
Version 2.0 (Bio-Rad Laboratories, Inc).
Murine Model of C. albicans Infection
Inoculum was prepared as described for injection of 200 ml of a 13 106 CFU/
mL suspension [8]. We observed discordance between cell counts and CFU
measurements for the tetO-HSP90/hsp90D strain in initial experiments,
such that CFU values werew60% lower than expected based on cell counts
[8]. A 10-fold increase in inoculum concentration for tetO-HSP90/hsp90D to
200 ml of 1 3 107 cells/mL producedw4-fold higher CFU/ml than the inoc-
ulum for the wild-type and the HSP90 heterozygote and thus was chosen
as the dose of tetO-HSP90/hsp90D for these experiments. Male CD1 mice
(Charles River Laboratories) age 8 weeks (weight 30–34 g) were infected
via the tail vein. For the wild-type and the HSP90 heterozygote, the sample
sizes were n = 5–13 mice per strain and treatment condition. For the tetO-
HSP90/hsp90D strain, the sample sizes were n = 22 mice for untreated
and n = 14 for tetracycline treated. Mice receiving tetracycline were given
sterile water supplemented with 2 mg/mL tetracycline (Sigma Biochemicals)
beginning 7 days prior to infection and continued until sacrifice. Water was
changed once daily. Daily weights during the 7-day lead in period were
taken to ensure that mice remained hydrated. Mice were observed three
times daily for signs of illness and weighed daily. At day 4 after injection,
mice were sacrificed by CO2 asphyxiation and the left kidney was removed
aseptically and homogenized in PBS, and serial dilutions were plated for
determination of kidney fungal burden, as described [8]. CFU values were
expressed as CFU/g of tissue, log-transformed, and compared with an
ANOVA with post-hoc testing of significance between groups (GraphPad
Prism 4.0). Murine work was performed under a protocol approved by the
Institutional Animal Use and Care Committee at Duke University Medical
Center.
Supplemental Data
Supplemental Data include Supplemental Experimental Procedures, six
figures, and three tables and can be found with this article online at http://
www.current-biology.com/supplemental/S0960-9822(09)00820-3.
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